What InnovAge (INNV) Said on Its Q1 Earnings Call
InnovAge (INNV) reported Q1 cost of care rose 12.7% to $85.5M, citing growth and higher expenses. The company is investing in care teams and technology to reduce costs. InnovAge reaffirmed its fiscal 2027 guidance, expecting revenue of $1.05B-$1.085B and adjusted EBITDA of $105M-$115M. Medicare rates are expected to increase 1.5%-2% from Jan 1, 2024.
How this was made

The 30-second read
Why it matters
Management attributed Q1 cost-of-care increases to member-month growth and higher per-participant costs, while describing operational steps to reduce assisted-living and nursing-facility costs. It also provided a detailed view of how V28 affects its PACE population and reiterated FY2027 guidance with a planned shift in the V28 blend during fiscal Q3.
Market read
The key tradable inputs are the reaffirmed FY2027 ranges, the expected Medicare rate increase effective Jan. 1, and the timing of the V28 blend shift, which together shape near-term margin and reimbursement expectations.
What to watch
The article highlights cost increases (salaries, pharmacy third-party fees, contract services, fleet costs) and de novo center losses; traders may underweight how these could pressure margins even with stable revenue guidance.
Background
InnovAge operates PACE programs for older adults and is transitioning its Medicare risk-adjustment exposure under the V28 model.
Ticker impact
InnovAge reaffirmed FY2027 guidance and discussed V28 Medicare risk-adjustment transition, including expected 1.5% to 2% Medicare rate increase effective Jan. 1.
Likely modest support as investors weigh reaffirmed FY2027 targets against ongoing reimbursement and cost headwinds from the V28 transition.
The article provides specific guidance ranges, V28 blend timing (90/10 to 50/50 in fiscal Q3), and cost drivers, but it does not introduce a new transaction or surprise print beyond the earnings-call disclosures.
Market effects
PACE and Medicare Advantage-adjacent healthcare operators may face similar reimbursement-model transition scrutiny, increasing focus on encounter-data quality and diagnosis mix.
No specific regional impact disclosed beyond market-level provider network investments.
Limited, as the disclosures are US Medicare reimbursement and company-specific guidance.
Counterpoint
Reaffirmed guidance may still embed optimistic assumptions about V28 phase-in reimbursement and cost containment, so downside risk remains if encounter-data submission or diagnosis mix deteriorates.
Key entities
- companyInnovAge
NASDAQ-listed PACE healthcare services provider that reaffirmed FY2027 guidance and discussed V28 Medicare risk-adjustment transition.
- policy/regulatoryV28 Medicare risk-adjustment model
New Medicare Advantage risk-adjustment framework discussed as creating reimbursement pressure for plans, with InnovAge arguing PACE eligibility criteria differ.
- technology/operationsEpic, data and analytics
Stated priorities under InnovAge 3.0 to support care teams and productivity, plus early-stage AI assessment for clinical decision support.


